The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes.
A. Oliver Sartor
Consultant or Advisory Role - Algeta; Bayer
Roy Amariglio
Employment or Leadership Position - Bayer
Scott Wilhelm
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Jose E. Garcia-Vargas
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
C. Gillies O'Bryan-Tear
Employment or Leadership Position - Algeta
Stock Ownership - Algeta
Minghua Shan
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Fang Fang
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Chris Parker
Consultant or Advisory Role - Algeta; Bayer; BN ImmunoTherapeutics
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen; Sanofi ; Takeda